reAlpha Tech Corp. (AIRE)
NASDAQ: AIRE · Real-Time Price · USD
0.3692
-0.0031 (-0.83%)
At close: Aug 1, 2025, 4:00 PM
0.3795
+0.0103 (2.79%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Revance Therapeutics.
Price Target: $0.00 (0.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 28, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $3 → $1.25 | Strong Buy | Maintains | $3 → $1.25 | +238.57% | May 21, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +712.57% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
4.45M
from 948.42K
Increased by 369.52%
Revenue Next Year
7.51M
from 4.45M
Increased by 68.67%
EPS This Year
-0.20
from -0.58
EPS Next Year
-0.16
from -0.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 5.5M | 8.1M | 15.9M |
| Avg | 4.5M | 7.5M | 15.4M |
| Low | 3.8M | 6.9M | 14.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 483.3% | 81.4% | 111.1% |
| Avg | 369.5% | 68.7% | 105.1% |
| Low | 304.4% | 54.8% | 97.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | -0.08 | -0.21 |
| Avg | -0.20 | -0.16 | -0.20 |
| Low | -0.24 | -0.23 | -0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.